Clinical Trial: Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma

Sponsor and Collaborators
University Hospital Heidelberg

Contact
Mathias Witzens-Harig, MD
+49 6221 568008

Principal Investigator
Mathias Witzens-Harig, MD
University of Heidelberg Hospital

Eva Lengfelder, MD
University of Mannheim Hospital

Ingo Schmidt-Wolf, MD
University of Bonn Hospital

ClinicalTrials.gov Identifier
NCT01933711

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs